Marburg

• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• Stopping tyrosine kinase inhibitors a second or third time after unsuccesful treatment discontinuation in chronic myeloid leukemia Pending
  2024-519472-69-00 4 CML-Patients in chronic phase having failed a prior attempt to stop im
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 5 Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 10 Demyelinating diseases
• Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending
  2025-523990-40-00 5 Newly diagnosed Multiple Myeloma in patients eligible for stem cell tr
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Recruiting
  2025-523443-35-00 5 2026-06-11 Persistent Corneal Epithelial Defect (PCED)
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting
  2025-524038-24-00 5 2026-05-22 Focal Epilepsy
• Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II stu … Recruiting
  2024-513155-32-00 4 2026-03-02 chronic spontaneous urticaria
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting
  2025-521260-35-00 6 2025-11-07 acute ischemic stroke and atrial fibrillation (AF)
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24 Idiopathic pulmonary fibrosis
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting
  2022-502286-16-00 5 2023-10-27 Primary Generalized Tonic-Clonic Seizures
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in … Recruiting
  2022-501152-28-00 4 2022-12-21 Breast Cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU … Recruiting
  2023-506414-46-00 5 2022-04-22 High risk patients defined as having at least one of the following ris
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer

Showing 1–24 of 182 trials